MASLD心脏代谢风险分层的影像生物标志物:CAC、EAT、CAP及LSM的增量价值
MASLD与CAC、高EAT、高CAP、高LSM的较高几率相关,连续变量中CAC和LSM也更高。这些发现代表组间影像差异,而非超越临床风险评分的增量预测价值。
要点
- MASLD患者CAC、EAT、CAP、LSM均较非MASLD者升高,提示并存不良影像负荷。
- CAC与MASLD关联的OR为1.41(95%CI 1.32-1.51),异质性I2=75.0%。
- 高EAT、高CAP、高LSM的OR分别为1.44、1.47、1.49,异质性均为0%。
核心结论
- MASLD与非MASLD者相比,钙化冠状动脉负荷、心包脂肪、肝脂肪变及肝硬度均持续更高。
- 这些发现是组间影像差异,应解释为并存不良影像负荷的证据,而非正式证明超越经验证临床风险引擎的增量预测价值。
- 上述生物标志物能否改善判别、重分类或净临床获益,尚需前瞻性验证及预设的增量预测分析。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Web of Science核心合集及Cochrane图书馆(2000年1月至2026年2月28日)。
- 主要结局为连续变量CAC(Agatston单位)、EAT(cm³)、CAP(dB/m)及LSM(kPa)。
- 采用随机效应模型(REML估计,必要时Hartung-Knapp校正)合并WMD及二分类阈值的OR,异质性用I2和τ2量化。
诊断标准与关键数值
- MASLD与亚临床疾病较高几率相关:CAC(OR 1.41,95%CI 1.32-1.51;I2=75.0%)。
- 高EAT(OR 1.44,95%CI 1.21-1.68;I2=0%)、高CAP(OR 1.47,95%CI 1.35-1.58;I2=0%)、高LSM(OR 1.49,95%CI 1.31-1.66;I2=0%)。
- 连续变量:MASLD者CAC高49.2 Agatston单位(95%CI 46.8-51.7;I2=75.4%),LSM高0.57 kPa(95%CI 0.46-0.68;I2=0%)。
- EAT(k=2;n=4306):WMD 76.18 cm³(95%CI 5.04-147.32;I2=98.3%),仅探索性,不适合点估计。
- CAP(k=2;n=6652):WMD 45.12 dB/m(95%CI 0.96-89.27;I2=98.1%),仅探索性,不适合点估计。
临床应用与阅片要点
- 在MASLD患者中阅片时,应关注CAC、EAT、CAP及LSM所反映的并存不良影像负荷。
- 上述指标与MASLD的关联为组间差异,不能直接用于个体化风险预测或替代临床风险评分。
- 将标准化影像协议整合进MASLD人群ASCVD风险表征需前瞻性研究验证。
局限性
- 纳入研究均为观察性(6项队列、10项横断面),无法确立因果或增量预测价值。
- EAT和CAP的合并分析仅基于2项研究,异质性极高(I2分别为98.3%和98.1%),仅作探索性。
- CAC连续变量分析异质性较高(I2=75.4%),CAC二分类阈值分析异质性I2=75.0%。
- 原文未报告超越PCE、SCORE2、FRS的判别、重分类或净临床获益的正式验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To systematically synthesize evidence on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and imaging biomarkers of subclinical atherosclerosis and hepatic steatosis/fibrosis, and to quantify the magnitude of these associations across study populations.
METHODS: We systematically searched PubMed, Embase, Web of Science Core Collection, and Cochrane Library (January 2000-February 28, 2026) for observational studies enrolling adults with MASLD (or historical NAFLD/MAFLD) that reported atherosclerotic cardiovascular disease (ASCVD)-related imaging outcomes. Primary outcomes were continuous coronary artery calcium (CAC; Agatston units), epicardial adipose tissue (EAT; cm3), controlled attenuation parameter (CAP; dB/m), and liver stiffness measurement (LSM; kPa). Weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for dichotomized thresholds were pooled using random-effects models with restricted maximum likelihood (REML) estimation and Hartung-Knapp adjustment where applicable; heterogeneity was quantified with I2 and τ2.
RESULTS: Sixteen observational studies (n = 34 713; 6 cohorts, 10 cross-sectional) from North America, Asia, and Europe were included. In modality-specific threshold analyses, MASLD was associated with higher odds of subclinical disease: CAC (OR 1.41, 95% CI: 1.32-1.51; I2 = 75.0%), high EAT (OR 1.44, 95% CI: 1.21-1.68; I2 = 0%), high CAP (OR 1.47, 95% CI: 1.35-1.58; I2 = 0%), and high LSM (OR 1.49, 95% CI: 1.31-1.66; I2 = 0%). For continuous outcomes, CAC was higher by 49.2 Agatston units (95% CI: 46.8-51.7; I2 = 75.4%) and LSM was higher by 0.57 kPa (95% CI: 0.46-0.68; I2 = 0%) in MASLD versus comparators. EAT (k = 2; n = 4306): WMD 76.18 cm³ (95% CI: 5.04-147.32; I2 = 98.3%) (exploratory only; not suitable for point estimation). CAP (k = 2; n = 6652): WMD 45.12 dB/m (95% CI: 0.96-89.27; I2 = 98.1%) (exploratory only; not suitable for point estimation).
CONCLUSIONS: MASLD is consistently associated with greater calcific coronary burden, pericoronary adiposity, hepatic steatosis, and hepatic stiffness relative to non-MASLD comparators. These findings represent between-group imaging differences and should be interpreted as evidence of concurrent adverse imaging burden rather than formal demonstration of incremental predictive value beyond validated clinical risk engines. Whether these biomarkers improve discrimination, reclassification, or net clinical benefit beyond established scores (Pooled Cohort Equations [PCE], SCORE2, Framingham Risk Score [FRS]) requires prospective validation with pre-specified incremental prediction analyses.
ADVANCES IN KNOWLEDGE: This study provides a comprehensive quantitative, multimodality synthesis demonstrating that MASLD is consistently associated with concurrent adverse changes across 4 key imaging biomarkers spanning subclinical atherosclerosis (CAC, EAT) and hepatic disease burden (CAP, LSM), establishing a critical evidence base to motivate prospective studies on integrating standardized imaging protocols to refine ASCVD risk characterization in MASLD populations.
引用
- Zhong J, He H, Zhao Y, et al. Imaging biomarkers for cardiometabolic risk stratification in metabolic dysfunction-associated steatotic liver disease: incremental value of coronary artery calcification, epicardial adipose tissue, controlled attenuation parameter, and liver stiffness measurement beyond clinical scores. Br J Radiol. 2026. PMID: 42143614. doi:10.1093/bjr/tqag112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。